

Regulatory Survey ION-1033

The data provided on this page is updated by the organisations.

The WMDA makes no representations or express or implied warranties regarding any information on this page.

Use of any information provided on this site does not and is not intended to create a contractual or other relationship.

General	
The information has been reviewed in year :	
Organisation name:	Gift of Life Marrow Registry
Organisation ION:	ION-1033
Country:	United States of America
Year the registry started operations:	1995

Products		comment
Do you provide HPC, Marrow?	yes	
Do you provide HPC, Apheresis?	yes	
Do you provide HPC, Cord Blood?	no	
Do you provide MNC, Apheresis?	yes	
Do you provide NC, Whole Blood?	no	

Product quantity		
Data valid for year		
Number of products	National	International
HPC, Marrow products:	20	5
HPC, Apheresis:	143	49
HPC, Cord:	0	0

License	
Organisation is licensed/accredited by the Competent Authority:	no
Comment:	
Name of Competent Authority:	
Date of last inspection:	
Link to website of Competent Authority:	
Can you provide the Legal documentation from the Competent Authority that your organisation is allowed to operate as a registry ?	
Is your registry WMDA Certified, WMDA Qualified or WMDA Accredited?	WMDA Accredited
The registry is accredited by any other organisation:	no
If yes, by which organisation?	

Affiliation	
The registry works with the following number of affiliated donor centres:	1
The registry audits its donor centres:	Yes
The registry works with the following number of affiliated collection centres:	16
The registry audits its collection centres:	Yes
The registry works with the following number of affiliated Cord Blood Banks:	

The registry audits its Cord Blood Banks:	
The registry works with the following number of affiliated transplant centres:	
The registry audits its transplant centres:	
The registry works with the following number of affiliated IDM Testing Laboratories:	2
The registry audits its IDM Testing Laboratories:	Yes
The registry works with the following number of affiliated HLA/other DNA markers testing laboratories:	4
The registry audits its HLA/other DNA markers testing laboratories:	Yes
The registry would be able to provide a full list of name/addresses of each affiliated and their licence/accreditation status, on request:	yes
The Cord Blood Banks are FACT-NetCord accredited:	
If yes, the following Cord Blood Bank(s) are accredited:	
The registry is able to provide a copy of all the certificates:	
Affiliated centres comply with WMDA Standards and applicable national regulations:	yes
The registry has requirements for affiliated centres in addition to WMDA Standards and applicable national regulations:	no
If yes, what are these requirements?	

Donor policy	
All donors are unpaid volunteers:	yes
All donors are informed about donation process and associated risks:	yes
Donors sign a valid informed consent to donate in the presence of a medical doctor/health care personnel/registry staff:	yes
The registry has systems in place to protect and control access to donor/patient records:	yes
The registry maintains donor anonymity:	yes
The registry has detailed donor evaluation and exclusion criteria in place:	yes
The registry has donor evaluation and exclusion criteria that do meet or exceed the WMDA guidelines:	yes

IDM

IDM	Tested	Method	Days between test and sampling/workup
ALT/ASTALT/AST ratio, De-Ritis-Quotient	-		
ChagasChagas, T. cruzi	Yes	chemiluminescent immunoassay or EIA	30
CMV IgGCytomegalovirus (CMV) Antibody testing IgG	On request		
CMV IgMCytomegalovirus (CMV) Antibody testing IgM	On request		
CMV TotalCytomegalovirus Total	Yes	Red Cell Adherence	30
EBV IgGEpstein-Barr Virus Antibody testing IgG	On request		
EBV IgMEpstein-Barr Virus Antibody testing IgM	On request		
HAV (NAT)Anti-hepatitis A virus nucleic acid testing	No		
HBV (NAT)Hepatitis B nucleic acid testing	Yes	NAT	30
HBc AbHepatitis B core antibody testing	Yes	chemiluminescent immunoassay or EIA	30
HBs AgHepatitis B Surface antigen testing	Yes	chemiluminescent immunoassay or EIA	30
HCV (NAT)Hepatitis C nucleic acid testing	Yes	NAT	30
HCV AbHepatitis C antibody testing	Yes	chemiluminescent immunoassay or EIA	30
HEV (NAT)Hepatitis E Virus nucleic acid testing	On request	NAT	30
HIV (NAT)Human Immunodeficiency Virus nucleic acid testing	Yes	NAT	30
HIV-1 AbHuman Immunodeficiency Virus HIV-1 antibody testing	Yes	chemiluminescent immunoassay or EIA	30

HIV-2 AbHuman Immunodeficiency Virus HIV-2 antibody testing	Yes	chemiluminescent immunoassay or EIA	30
HIV p24Human Immunodeficiency Virus p24 antigen testing	On request	chemiluminescent immunoassay or EIA	30
HTLV-IHuman T-Lymphotropic Virus type I testing	Yes	chemiluminescent immunoassay or EIA	30
HTLV-IIHuman T-Lymphotropic Virus type II testing	Yes	chemiluminescent immunoassay or EIA	30
MalariaMalaria	On request	PCR	30
HSVHerpes Simplex Virus	On request	ABY or PCR	30
STSSerological tests for syphilis	Yes	Agglutination or EIA	30
STS FTA-ABSSerological test for syphilis	On request	FTA-ABS	
ToxoplasmosisToxoplasmosis	No	ABY	30
VZVVaricella Zoster Virus	No		
WNV-NATWest Nile Virus nucleic acid testing	Yes	NAT	30
Other tests performed	No		

Testing

The physical and medical exam at donor workup is performed by a medical doctor:	y es
All donor testing (at workup) for infectious disease is performed in a laboratory certified/licensed by a Competent Authority:	y es
HLA typing for patient specific request is performed in an appropriately accredited laboratory:	y es
Sterility testing is performed on the adult donor product:	y es
Sterility testing is performed on the cord blood product:	
Screening questionnaire to exclude communicable disease:	y es
Screening questionnaire to exclude donors with 'high risk' lifestyles:	y es
Donor reliability identified by a medical doctor:	y es
Donor clearance to donate is confirmed by a medical doctor, following as a minimum the donor exclusion criteria in Annex 1 of EU Directive 2006/17/EC : The party providing the cell product must exclude donors when: • They are pregnant; • They are breastfeeding; • There is the potential for transmission of inherited conditions; • There is evidence of any other risk factors for transmissible diseases on the basis of a risk assessment, taking into consideration <i>Donor travel and exposure history and local infectious disease prevalence</i>; • There is presence on the donor's body of physical signs implying a risk of transmissible disease(s); • There is a history of a disease of unknown aetiology; • There is a risk of transmission of diseases caused by prions; • There is systemic infection which is not controlled at the time of donation, including bacterial diseases, systemic viral, fungal or parasitic infections, or significant local infection in the tissues and cells to be donated; • There is history of chronic, systemic autoimmune disease that could have a detrimental effect on the quality of the Cell Product; • There is recent history of vaccination with a live attenuated virus where a risk of transmission is considered to exist; • There is ingestion of, or exposure to, a substance (such as cyanide, lead, mercury, gold) that may be transmitted to recipients in a dose that could endanger their health.	y es

Customs regulations

Are there any customs regulations to follow, or customs paperwork required, to import cell products into the organisation country? If yes, please specify:	
Are there any customs regulations to follow, or customs paperwork required, to export cell products from the organisation country? If yes, please specify:	
Are there any import regulations to follow, or paperwork required, to import cell products into the organisation country? If yes, please specify:	

Are there any export regulations to follow, or paperwork required, to export cell products from the organisation country? If yes, please specify:	
---	--

Reporting of Serious Adverse Events

Please indicate which of the following schemes for reporting Serious Adverse Events relating to either the Donor or the product the Registry participates in:

- Mandatory National Reporting Scheme	no
- Voluntary National Reporting Scheme	no
- WMDA SEAR/SPEAR Reporting Scheme	y es
The registry will notify the receiving Registry within 24 hours of receiving information relating to any serious adverse event that could be considered to affect the patient receiving the product:	y es

Quality management

The registry does maintain Standard Operating Procedures for your work:	yes
The registry would be willing to provide these to WMDA or another registry upon request:	yes
The registry would be willing to provide WMDA or another registry, on request, with copies of any packaging the HPC product will arrive in:	yes
Donor records relating to the medical exam and HPC collection process are the following number(s) of year(s) retained:	Indefinitely